Proteins or polypeptide drugs with improved therapeutic value can be obtained by covalent linkage to soluble, biocompatible polymers, since these conjugates may lead to decreased antigenicity and immunogenicity, reduced renal filtration, resistance to proteolytic enzymes and enhanced residence time in blood.
End functionalized PVP as new oligomer for enzyme modification
SCHIAVON, ODDONE;CALICETI, PAOLO;VERONESE, FRANCESCO
2001
Abstract
Proteins or polypeptide drugs with improved therapeutic value can be obtained by covalent linkage to soluble, biocompatible polymers, since these conjugates may lead to decreased antigenicity and immunogenicity, reduced renal filtration, resistance to proteolytic enzymes and enhanced residence time in blood.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
